Bank of America began coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a research report sent to investors on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $38.00 price objective on the stock.
Separately, Evercore ISI started coverage on shares of Metsera in a research report on Tuesday. They set an “outperform” rating on the stock.
View Our Latest Stock Analysis on MTSR
Metsera Stock Down 8.1 %
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Articles
- Five stocks we like better than Metsera
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Using the MarketBeat Stock Split Calculator
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
